Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

Basit Öğe Kaydı
dc.contributor.authorÜstündağ, Sedat
dc.contributor.authorDoğan, Ekrem
dc.contributor.authorDuranay, Murat
dc.contributor.authorKazancıoğlu, Rümeyza
dc.contributor.authorÇelik, Vedat
dc.contributor.authorÜnsal, Abdülkadir
dc.contributor.authorYıldız, Alaattin
dc.date.accessioned2021-11-20T10:10:03Z
dc.date.available2021-11-20T10:10:03Z
dc.date.issued2016
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalıen_US
dc.description.abstractBackground: We investigated the efficacy, safety and tolerability of once-monthly administration of C.E.R.A. in erythropoiesis stimulating agents (ESAs) naive predialysis patients with CKD for anemia treatment Study Design: Single arm, open label study. Methods: A total of 75 patients (mean (SD) age was 52.8 (16.4) years, 76.0% were female) were included in this study conducted between 12 August 2008 and 30 October 2009 in 9 centers across Turkey. The mean change in Hb concentration (g/dL) between baseline (week 0) and the efficacy evaluation period (EEP) was the primary efficacy parameter evaluated in three consecutive periods including a dose titration period (DTP; with initial 1.2 ?g/kg dose of C.E.R.A., subcutaneously, 28 weeks), EEP (8 weeks) and a long-term safety period (16 weeks). Results: Our analysis revealed an improvement in Hb levels from baseline value of 9.4 (0.4) g/dL to time adjusted average level of 11.4 (0.7) g/dL in EEP in the per protocol (PP) population and from 9.3 (0.5) g/dL to 11.1 (1.0) g/dL in intent-to-treat (ITT) population. Mean (SD) change in Hb levels from baseline to EEP was 2.0 (0.7) g/dl in the PP population (primary endpoint) and 1.7 (1.1) g/dL in the ITT population. The percentage of patients whose Hb concentrations remained within the target range of 10.0-12.0 g/dL throughout the EEP was 43.9% (95% CI: 28.5-60.3%) in the PP population and 38.7% (95% CI: 27.6% to 50.6%) in the ITP population. A total of 206 adverse events (AE) were reported in 77.0% of patients with hypertension (20%) as the most frequent AE. Conclusion: Once-monthly subcutaneous C.E.R.A. administration is effective and safe in the treatment of anemia in pre-dialysis patients with CKD, who are not currently treated with ESAs.en_US
dc.identifier.endpage330en_US
dc.identifier.issn2146-3123
dc.identifier.issn2146-3131
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-84971612089en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage322en_US
dc.identifier.trdizinid238436en_US
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TWpNNE5ETTJOZz09
dc.identifier.urihttps://hdl.handle.net/20.500.14551/5479
dc.identifier.volume33en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofBalkan Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240608_ID_Qen_US
dc.subjectCerrahien_US
dc.titleSubcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5479.pdf
Boyut:
446.6 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Balkan Medical Journal
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu